Antibody Drug Conjugates (ADCs) are one of the fastest-growing classes of cancer drugs in clinical development and have the potential to change the management of cancer patients. Unfortunately, ADCs have been associated with the risk of pulmonary abnormalities, the most concerning of which is drug-induced Interstitial Lung Disease (ILD).
As a result, in clinical trials investigating ADCs for the treatment of cancers, regulatory agencies around the world are asking trial sponsors to monitor for ILD toxicity. Research has shown that early detection, diagnosis, and management can prevent the worsening of ILD in these patients since in many cases the complications are reversible.
This webinar will review the implications of ILD toxicity monitoring in ADC trials. Dr. Sood will present best practices for using HRCT for the detection and characterization of ILD and how, when integrated with clinical and laboratory tests, it provides a consistent and standardized way to adjudicate ILD cases and meet regulators’ expectations.
Date: 14 May, 2024
Time: 16.00 CEST
Venue: Online